CLAIMS

1. An isolated polypeptide comprising a protein S gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain, wherein the polypeptide further comprises an EGF domain.

2. The polypeptide of claim 1, wherein the EGF domain is from Protein S.

3. The polypeptide of any one of claims 1 to 2, wherein the polypeptide further comprises a detectable label.

4. The polypeptide of claim 3, wherein the detectable label is a fluorescent label, a chemilluminescent label, a radiolabel, an enzyme, a dye or a ligand.

5. The polypeptide of any one of claims 1 to 4, wherein said polypeptide further comprises a therapeutic agent.

6. The polypeptide of claim 5, wherein said therapeutic agent is selected from the group consisting of a radionuclide, a chemotherapeutic agent, a toxin, an anti-inflammatory, an immune-modulating composition, a beta blocker, an anti-hypertensive, a cardiotonic, an anti-thrombotic, a vasodilator, a hormone antagonist, an endothelin antagonist, a cytokine inhibitor/blocker, a clcium channel blocker, a phosphodiesterase inhibitor, an angiotensin type 2 antagonist, an anti-coagulant and an anti-viral agent.

7. The polypeptide of claim 6, wherein the chemotherapeutic agent selected from the group consisting of temozolomide, epothilones, melphalan, carmustine, busulfan, lomustine, cyclophosphamide, dacarbazine, polifeprosan, ifosfamide, chlorambucil, mechlorethamine, busulfan, cyclophosphamide, carboplatin, cisplatin, thiotepa, capecitabine, streptozocin, bicalutamide, flutamide, nilutamide, leuprolide acetate, doxorubicin hydrochloride, bleomycin sulfate, daunorubicin hydrochloride, dactinomycin, liposomal daunorubicin citrate, liposomal doxorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, mitomycin, doxorubicin, valrubicin, anastrozole, toremifene citrate, cytarabine, fluorouracil, fludarabine, floxuridine, interferon α-2b, plicamycin, mercaptopurine, methotrexate, interferon α - 2a, medroxyprogersterone acetate, estramustine phosphate sodium, estradiol, leuprolide acetate, megestrol acetate, octreotide acetate, deithylstilbestrol diphosphate, testolactone, goserelin acetate, etoposide phosphate, vincristine sulfate, etoposide, vinblastine, etoposide, vincristine sulfate, teniposide, trastuzumab, gemtuzumab ozogamicin, rituximab, exemestane, irinotecan hydrocholride, asparaginase, gemcitabine hydrochloride, altretamine, topotecan hydrochloride, hydroxyurea,

cladribine, mitotane, procarbazine hydrochloride, vinorelbine tartrate, pentrostatin sodium, mitoxantrone, pegaspargase, denileukin diftitix, altretinoin, porfimer, bexarotene, paclitaxel, docetaxel, arsenic trioxide and tretinoin.

8. The polypeptide of claim 6, wherein the toxin is selected from the group consisting of Pseudomonas exotoxin (PE38), ricin A chain, diphtheria toxin, Pokeweed antiviral protein (PAP), saporin and gelonin.

9. The polypeptide of claim 6, wherein the radionuclide is selected from Y-90, P-32, I-131, In-111, Sr-89, Re-186, Sm-153 and Sn-117m.

10. The polypeptide of claim 6, wherein the anti-inflammatory or the immune-modulating composition is selected from the group consisting of prednisone, methylprednisone, Venipred, Celestone, hydrocortisone, triamcinoclone, Aristonpan Intra-Articular injection, Methapred, Rayos oral, betamethasone, and etanercept.

11. The polypeptide of claim 6, wherein the anti-viral agent is selected from the group consisting of Abacavir, Aciclovir, Acyclovir, Adefovir, Amantadine, Amprenavir, Ampligen, Arbidol, Atazanavir, Atripla, Boceprevirertet, Cidofovir, Combivir, Darunavir, Delavirdine, Didanosine, Docosanol, Edoxudine, Efavirenz, Emtricitabine, Enfuvirtide, Entecavir, Entry inhibitors, Famciclovir, Fomivirsen, Fosamprenavir, Foscarnet, Fosfonet, Ganciclovir, Ibacitabine, Imunovir, Idoxuridine, Imiquimod, Indinavir, Inosine, Integrase inhibitor, Interferon type III, Interferon type II, Interferon type I, Interferon, Lamivudine, Lopinavir, Loviride, Maraviroc, Moroxydine, Methisazone, Nelfinavir, Nevirapine, Nexavir, Nucleoside analogues, Oseltamivir, Peginterferon alfa-2a, Penciclovir, Peramivir, Pleconaril, Podophyllotoxin, Protease inhibitor, Raltegravir, Reverse transcriptase inhibitor, Ribavirin, Rimantadine, Ritonavir, Pyramidine, Saquinavir, Stavudine, Synergistic enhancer (antiretroviral), Tea tree oil, Telaprevir, Tenofovir, Tenofovir disoproxil, Tipranavir, Trifluridine, Trizivir, Tromantadine, Truvada, Valaciclovir, Valganciclovir, Vicriviroc, Vidarabine, Viramidine, Zalcitabine, Zanamivir or Zidovudine.

12. The polypeptide of any one of claims 1 to 11, wherein the polypeptide further comprises an antibody Fc region.

13. The polypeptide of any one of claims 1 to 12, wherein the polypeptide comprises 9 to 13 Gla residues.

14. The polypeptide of any one of claims 1 to 13, wherein the polypeptide comprises at least one disulfide bond.

15. The polypeptide of any one of claims 1 to 14, wherein the polypeptide is between 4.5 and 30 kD in size.

16. The polypeptide of any one of claims 1 to 15, wherein the polypeptide further comprises a Kringle domain.